These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20825720)

  • 1. [Clinical evaluation of valsartan on portal hypertension in patients with hepatic cirrhosis].
    Huo LJ; Zhang SJ; Liu Y
    Zhonghua Gan Zang Bing Za Zhi; 2010 Aug; 18(8):622-3. PubMed ID: 20825720
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
    Fierbinteanu-Braticevici C; Dragomir P; Tribus L; Negreanu L; Bengus A; Usvat R; Andronescu D
    J Gastrointestin Liver Dis; 2006 Dec; 15(4):337-42. PubMed ID: 17205144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short term effects of valsartan on portal blood flow in cirrhotic patients.
    Yalniz M; Demir A; Arslan A; Cihangiroğlu M
    Turk J Gastroenterol; 2003 Mar; 14(1):18-25. PubMed ID: 14593533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of angiotensin II type 1 receptor blocker valsartan in rats with portal hypertensive gastropathy].
    Huo LJ; Huang HF; Yang BY
    Zhonghua Gan Zang Bing Za Zhi; 2006 Aug; 14(8):611-3. PubMed ID: 16938177
    [No Abstract]   [Full Text] [Related]  

  • 5. The angiotensin II receptor antagonist candesartan is not effective in reducing portal hypertension in patients with cirrhosis.
    Heim MH; Jacob L; Beglinger C
    Digestion; 2007; 75(2-3):122-3. PubMed ID: 17630472
    [No Abstract]   [Full Text] [Related]  

  • 6. [The use of anaprilin for the correction of portal hypertension in liver cirrhosis].
    Bondarenko IP; Dubinskiĭ AA; Tereshkin IG
    Vrach Delo; 1989 Nov; (11):19-22. PubMed ID: 2609578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correction of portal hypertension and renal dysfunction with help of nebivolol and lizinopril in patients with hepatic cirrhosis].
    Fedulenkova LV
    Eksp Klin Gastroenterol; 2009; (5):130-7. PubMed ID: 20201315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle?].
    Klein CP
    Dtsch Med Wochenschr; 1985 Nov; 110(46):1774-6. PubMed ID: 4054003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinico-pathogenetic and pharmacotherapeutic aspects of portal hypertension in liver cirrhosis].
    Ryss ES; Fishzon-Ryss IuI
    Ter Arkh; 1989; 61(8):65-8. PubMed ID: 2686074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension.
    Hernández-Guerra M; García-Pagán JC; Turnes J; Bellot P; Deulofeu R; Abraldes JG; Bosch J
    Hepatology; 2006 Mar; 43(3):485-91. PubMed ID: 16496307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan in preascitic cirrhosis.
    Castaño G; Viudez P; Sookoian S
    Am J Gastroenterol; 2004 Nov; 99(11):2282-3. PubMed ID: 15555016
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of molsidomine on portal and cardiac hemodynamics in liver cirrhosis].
    Hüppe D; Jäger D; Tromm A; Tunn S; Barmeyer J; May B
    Dtsch Med Wochenschr; 1991 May; 116(22):841-5. PubMed ID: 2036943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Functional factors which contribute to portal hypertension in hepatic cirrhosis].
    Orrego Matte H
    Medicina (B Aires); 1970; 30(4):399-401. PubMed ID: 5487697
    [No Abstract]   [Full Text] [Related]  

  • 15. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
    Berzigotti A; Bellot P; De Gottardi A; Garcia-Pagan JC; Gagnon C; Spénard J; Bosch J
    Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug therapy of pulmonary and portal hypertension in liver cirrhosis].
    Vorob'ev LP; Maev IV; Andreev NG
    Klin Med (Mosk); 1991 Feb; 69(2):64-7. PubMed ID: 1875666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The hypotensive effect and tolerance of valsartan (Diovan) in hypertension in a general clinical practice].
    Ivleva AIa; Sokolova MA; Moiseev VS
    Ter Arkh; 1999; 71(2):67-70. PubMed ID: 10222559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valsartan for hypertension.
    Med Lett Drugs Ther; 1997 Apr; 39(999):43-4. PubMed ID: 9137296
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hemodynamic disorders due to liver cirrhosis].
    Garbuzenko DV
    Klin Med (Mosk); 1996; 74(2):5-7. PubMed ID: 8772089
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of valsartan and captopril in patients with essential hypertension in Indonesia.
    Prabowo P; Arwanto A; Soemantri D; Sukandar E; Suprihadi H; Parsudi I; Markum MS; Kabo P; Atmoko R; Prodjosudjadi W
    Int J Clin Pract; 1999 Jun; 53(4):268-72. PubMed ID: 10563070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.